Printer friendly
Acronymfinder

What does CAP stand for?

CAP stands for Community-Acquired Pneumonia


This definition appears very rarely and is found in the following Acronym Finder categories:

  • Science, medicine, engineering, etc.

See other meanings of CAP

Other Resources:
We have 1492 other definitions for CAP in our Acronym Attic

Samples in periodicals archive:

March 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, following its expected launch later this year in the United States and in 2011 in Europe and Japan, Forest Laboratories/AstraZeneca/Takeda's ceftaroline will earn peak year sales of up to $200 million in the community-acquired pneumonia drug market.
The drug is currently also being studied in a second complicated skin infection trial (STRAUSS II) targeting both Gram-positive and Gram-negative bacterial infections, including patients with diabetic foot infections; and in phase III clinical trials in nosocomial pneumonia (CHOPIN studies) and in patients hospitalized with community-acquired pneumonia.
for the treatment of penicillin-resistant Streptococcus pneumoniae in community-acquired pneumonia (CAP) This new indication makes Levaquin the first prescription antimicrobial agent specifically indicated for CAP caused by this resistant bacterium, giving physicians an additional option when penicillin-resistant pneumococcal pneumonia is present or suspected.
Californians hospitalized with community-acquired pneumonia (CAP) could more than double their chances of survival if they are treated at one of the top-rated hospitals, according to a newly released report from the Office of Statewide Health Planning and Development (OSHPD), "Community Acquired Pneumonia: Hospital Outcomes in California, 2003-2005.
8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the patent expiries of three blockbuster antibiotics -- levofloxacin, moxifloxacin and piperacillin/tazobactam -- will be the primary factors contributing to a decline of more than 15 percent in the community-acquired pneumonia drug market though 2018.